索替赛普在艾森曼格综合征患者中的应用。

IF 2.5 4区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

Pulmonary Circulation Pub Date : 2026-03-10 eCollection Date: 2026-01-01 DOI:10.1002/pul2.70283

Oktay Tutarel, Oliver Miera, Felix Berger

{"title":"索替赛普在艾森曼格综合征患者中的应用。","authors":"Oktay Tutarel, Oliver Miera, Felix Berger","doi":"10.1002/pul2.70283","DOIUrl":null,"url":null,"abstract":"Eisenmenger syndrome represents a complex and severe form of pulmonary arterial hypertension (PAH) associated with congenital heart disease. Sotatercept, a first-in-class activin-signaling inhibitor, offers a novel therapeutic approach in the treatment of PAH, and has emerged as a promising therapeutic agent. However, patients with Eisenmenger syndrome were not included in its pivotal trials. Therefore, data regarding its effect in this patient cohort is lacking. We present two cases of patients with Eisenmenger syndrome treated with sotatercept. Sotatercept improved the subjective and objective exercise capacity in both patients without any significant adverse side effects.","PeriodicalId":20927,"journal":{"name":"Pulmonary Circulation","volume":"16 1","pages":"e70283"},"PeriodicalIF":2.5000,"publicationDate":"2026-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12974322/pdf/","citationCount":"0","resultStr":"{\"title\":\"Sotatercept in Patients With Eisenmenger Syndrome.\",\"authors\":\"Oktay Tutarel, Oliver Miera, Felix Berger\",\"doi\":\"10.1002/pul2.70283\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Eisenmenger syndrome represents a complex and severe form of pulmonary arterial hypertension (PAH) associated with congenital heart disease. Sotatercept, a first-in-class activin-signaling inhibitor, offers a novel therapeutic approach in the treatment of PAH, and has emerged as a promising therapeutic agent. However, patients with Eisenmenger syndrome were not included in its pivotal trials. Therefore, data regarding its effect in this patient cohort is lacking. We present two cases of patients with Eisenmenger syndrome treated with sotatercept. Sotatercept improved the subjective and objective exercise capacity in both patients without any significant adverse side effects.\",\"PeriodicalId\":20927,\"journal\":{\"name\":\"Pulmonary Circulation\",\"volume\":\"16 1\",\"pages\":\"e70283\"},\"PeriodicalIF\":2.5000,\"publicationDate\":\"2026-03-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12974322/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pulmonary Circulation\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1002/pul2.70283\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2026/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pulmonary Circulation","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/pul2.70283","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

摘要

艾森曼格综合征是一种复杂而严重的肺动脉高压（PAH），与先天性心脏病相关。Sotatercept是一种一流的激活素信号抑制剂，为治疗多环芳烃提供了一种新的治疗方法，并已成为一种有前景的治疗药物。然而，艾森曼格综合征患者未被纳入关键试验。因此，缺乏关于其在该患者队列中的效果的数据。我们报告两例艾森门格综合征患者用索替赛普治疗。索替赛普改善了两例患者的主观和客观运动能力，无明显不良副作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

Sotatercept in Patients With Eisenmenger Syndrome.

查看原文本刊更多论文

Sotatercept in Patients With Eisenmenger Syndrome.

Eisenmenger syndrome represents a complex and severe form of pulmonary arterial hypertension (PAH) associated with congenital heart disease. Sotatercept, a first-in-class activin-signaling inhibitor, offers a novel therapeutic approach in the treatment of PAH, and has emerged as a promising therapeutic agent. However, patients with Eisenmenger syndrome were not included in its pivotal trials. Therefore, data regarding its effect in this patient cohort is lacking. We present two cases of patients with Eisenmenger syndrome treated with sotatercept. Sotatercept improved the subjective and objective exercise capacity in both patients without any significant adverse side effects.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Pulmonary Circulation Medicine-Pulmonary and Respiratory Medicine

CiteScore

4.20

自引率

11.50%

发文量

153

审稿时长

15 weeks

期刊介绍： Pulmonary Circulation''s main goal is to encourage basic, translational, and clinical research by investigators, physician-scientists, and clinicans, in the hope of increasing survival rates for pulmonary hypertension and other pulmonary vascular diseases worldwide, and developing new therapeutic approaches for the diseases. Freely available online, Pulmonary Circulation allows diverse knowledge of research, techniques, and case studies to reach a wide readership of specialists in order to improve patient care and treatment outcomes.